Japan · Delayed Price · Currency is JPY Terumo Earnings Call Transcripts
Fiscal Year 2026
-
Record-high revenue and profits were achieved, driven by strong North American demand and effective pricing strategies that offset tariffs and FX headwinds. Acquisitions of Leverkusen Plant and OrganOx contributed to results, and the company remains on track to meet GS 2026 targets.
-
Global sales growth is driven by innovation in vascular access, CDMO, and blood technologies, with a focus on margin expansion and strategic M&A. OrganOx acquisition is expected to deliver high double-digit growth and significant market impact, while U.S., Japan, China, and India remain key markets.
-
Record first-half revenue and profits were achieved, driven by strong North American demand, pricing measures, and cost control. Full-year guidance was revised upward, with strategic investments and the Organox acquisition expected to fuel further growth.
-
Preparations for the Lacanbi auto injector launch are progressing, with cardiovascular growth led by volume and sustainable price increases. Significant compensation was received for a prior project cancellation, and China neuro sales rose due to VBP volume commitments.
Fiscal Year 2025
-
The acquisition of OrganOx for $1.5 billion enables entry into the high-growth organ transplantation market, leveraging innovative NMP technology to address unmet needs and expand into new domains. Synergies, cost advantages, and a strong strategic fit are expected to drive long-term growth.
-
Fiscal 2024 saw record revenue, profit, and free cash flow, driven by global demand and strategic restructuring. Outlook for 2025 is strong, with further margin improvement and global CDMO expansion, though U.S. tariffs pose a risk.
-
Record revenue and profit highs were achieved, driven by strong U.S. and global demand, effective pricing, and favorable forex. One-time restructuring and impairment costs were recorded, but underlying business momentum remains robust, with steady progress toward full-year targets.
-
Record half-year highs in sales, profits, and free cash flow were achieved, driven by strong demand, cost control, and favorable FX. Full-year guidance was raised, with innovation and expansion into the venous intervention market highlighted as key growth drivers.
-
Record quarterly highs in revenue and profit were achieved, driven by strong demand, pricing measures, and favorable exchange rates. All segments and regions posted robust growth, with continued margin improvement and cautious guidance maintained amid macroeconomic uncertainties.